Annovis to present at the h.c. wainwright 27th annual global investment conference

Malvern, pa., sept. 02, 2025 (globe newswire) -- annovis bio, inc. (nyse: anvs) ("annovis" or the “company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as alzheimer's disease (ad) and parkinson's disease (pd), today announced its ceo, maria maccecchini, ph.d.

ANVS Ratings Summary

ANVS Quant Ranking